{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:45:25Z","timestamp":1784249125057,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103047","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:59:15Z","timestamp":1763326755000},"page":"103047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis"],"prefix":"10.1016","volume":"141","author":[{"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103047_b0010","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103047_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103047_b0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/clinchem\/hvac122","article-title":"Urinary cell-free DNA in liquid biopsy and cancer management","volume":"68","author":"Salfer","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2025.103047_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103455","article-title":"Size distribution of cell-free DNA in oncology","volume":"166","author":"Udomruk","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2025.103047_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1458362","article-title":"Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials","volume":"12","author":"Huang","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ctrv.2025.103047_b0035","doi-asserted-by":"crossref","unstructured":"Wever BMM, Steenbergen RDM. Unlocking the potential of tumor-derived DNA in urine for cancer detection: methodological challenges and opportunities. Mol Oncol. Published online March 10, 2024. doi:10.1002\/1878-0261.13628.","DOI":"10.1002\/1878-0261.13628"},{"key":"10.1016\/j.ctrv.2025.103047_b0040","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103047_b0045","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.21037\/apm-22-204","article-title":"QUADAS-2 tool for quality assessment in diagnostic meta-analysis","volume":"11","author":"Huang","year":"2022","journal-title":"Ann Palliat Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103047_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tree.2008.10.008","article-title":"Generalized linear mixed models: a practical guide for ecology and evolution","volume":"24","author":"Bolker","year":"2009","journal-title":"Trends Ecol Evol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103047_b0055","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jclinepi.2003.12.019","article-title":"Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis","volume":"57","author":"Macaskill","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2025.103047_b0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-11-22","article-title":"Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study","volume":"11","author":"Schroll","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"Pt A","key":"10.1016\/j.ctrv.2025.103047_b0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ctrv.2025.103047_b0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-0716-1566-9_12","article-title":"Network meta-analysis","volume":"2345","author":"Watt","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103047_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0080","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103047_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024625","article-title":"Empirical evaluation of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using Cohen's kappa","volume":"9","author":"Daly","year":"2019","journal-title":"BMJ Open"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103047_b0090","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1001\/jama.2018.17977","article-title":"Bayesian hierarchical models","volume":"320","author":"McGlothlin","year":"2018","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103047_b0095","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.3758\/s13428-022-02008-x","article-title":"Failing to attend versus failing to stop: single-trial decomposition of action-stopping in the stop signal task","volume":"55","author":"Hannah","year":"2023","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.ctrv.2025.103047_b0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2288-14-70","article-title":"Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study","volume":"14","author":"van Enst","year":"2014","journal-title":"BMC Med Res Method"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103047_b0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103047_b0110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/jalm\/jfae117","article-title":"Assessing adherence to the PRISMA-DTA guideline in diagnostic test accuracy systematic reviews: a five-year follow-up analysis","volume":"10","author":"Salameh","year":"2025","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0115","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/s41598-021-81900-6","article-title":"Detection of colorectal cancer in urine using DNA methylation analysis","volume":"11","author":"Bach","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2025.103047_b0120","article-title":"ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine","volume":"5","author":"Pellini","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/CBM-182344","article-title":"Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer","volume":"27","author":"Yu","year":"2020","journal-title":"Cancer Biomark"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103047_b0130","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.3390\/cancers13205128","article-title":"A real-world application of liquid biopsy in metastatic colorectal cancer: the Poseidon study","volume":"13","author":"Procaccio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103047_b0135","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1016\/j.ejso.2021.07.017","article-title":"Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer","volume":"47","author":"Ohta","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103047_b0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12094-017-1754-7","article-title":"Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC","volume":"20","author":"Xie","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103047_b0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3233\/CBM-181511","article-title":"Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients","volume":"23","author":"Zhang","year":"2018","journal-title":"Cancer Biomark"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103047_b0150","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.21037\/jtd.2018.06.50","article-title":"Urinary circulating DNA profiling in non-small cell lung cancer patients following treatment shows prognostic potential","volume":"10","author":"Hu","year":"2018","journal-title":"J Thorac Dis"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103047_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23321","article-title":"Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer","volume":"34","author":"Ren","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.ctrv.2025.103047_b0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lungcan.2022.06.013","article-title":"Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: a feasibility study","volume":"170","author":"Wever","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103047_b0165","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12094-016-1534-9","article-title":"Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs","volume":"19","author":"Chen","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103047_b0170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s12094-017-1669-3","article-title":"Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients","volume":"19","author":"Li","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103047_b0175","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-19-2896","article-title":"Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103047_b0180","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/cam4.1935","article-title":"Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103047_b0185","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103047_b0190","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41416-022-01706-9","article-title":"Urine DNA biomarkers for hepatocellular carcinoma screening","volume":"126","author":"Kim","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0195","doi-asserted-by":"crossref","first-page":"21585","DOI":"10.1038\/s41598-023-48500-y","article-title":"Novel urine cell-free DNA methylation markers for hepatocellular carcinoma","volume":"13","author":"Lin","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103047_b0200","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/diagnostics11081475","article-title":"Detection of CTNNB1 hotspot mutations in cell-free DNA from the urine of hepatocellular carcinoma patients","volume":"11","author":"Lin","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103047_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/CBM-190523","article-title":"Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients","volume":"28","author":"Guan","year":"2020","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.ctrv.2025.103047_b0210","article-title":"Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA","volume":"40(11):BSR20194306","author":"Zuo","year":"2020","journal-title":"Biosci Rep"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103047_b0215","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12094-017-1825-9","article-title":"Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse","volume":"20","author":"Liu","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103047_b0220","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-21-3710","article-title":"HPV and DNA methylation testing in urine for cervical intraepithelial neoplasia and cervical cancer detection","volume":"28","author":"van den Helder","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103047_b0225","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691681","article-title":"Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients","volume":"39","author":"Shi","year":"2017","journal-title":"Tumour Biol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103047_b0230","doi-asserted-by":"crossref","first-page":"16110","DOI":"10.3390\/ijms232416110","article-title":"Urine molecular biomarkers for detection and follow-up of small renal masses","volume":"23","author":"\u017dalimas","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103047_b0235","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177759","article-title":"ctDNA transiting into urine is ultrashort and facilitates noninvasive liquid biopsy of HPV+ oropharyngeal cancer","volume":"9","author":"Bhambhani","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2025.103047_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2023.115318","article-title":"Mutation detection of urinary cell-free DNA via catch-and-release isolation on nanowires for liquid biopsy","volume":"234","author":"Takahashi","year":"2023","journal-title":"Biosens Bioelectron"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103047_b0245","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-16-2592","article-title":"Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers","volume":"23","author":"Fujii","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2025.103047_b0250","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e22175","article-title":"Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers","volume":"32","author":"Janku","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:49:57Z","timestamp":1764143397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S0305737225001690"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103047","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103047"}}